<DOC>
	<DOC>NCT02181686</DOC>
	<brief_summary>The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.</brief_summary>
	<brief_title>Iperia/Sentus QP Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<criteria>Patient is able to understand the nature of the study and provides written informed consent. Patient meets a standard indication for CRTD (Sentus QP group) or ICD therapy. Patient is able and willing to complete the planned followup visits at the investigational site. Patient accepts the Home Monitoring® concept. Age is ≥ 18 years. Sentus QP group only: Patient is a candidate for a new (de novo) implant or an upgrade from an existing ICD or pacemaker utilizing a BIOTRONIK Sentus QP lead Patient has a standard contraindication for CRTD (Sentus QP group) or ICD therapy. Sentus QP group only: Currently implanted with an endocardial or epicardial LV lead or had prior attempt to place a LV lead. Sentus QP group only: Cardiac surgery procedure (coronary bypass graft, valve surgery, or ablation) that is planned to occur within 3 months after implantation. Patient is expected to receive ventricular assist device or heart transplantation within the next 3 months. Patient is pregnant or breastfeeding. Life expectancy of less than 3 months Participating in another cardiac clinical investigation with active treatment arm.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Iperia ICD family</keyword>
	<keyword>Sentus QP left ventricular lead</keyword>
	<keyword>Quadripolar CRT-D system</keyword>
</DOC>